Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal Cuff Infiltration With Liposomal Bupivacaine for Pain Relief
NCT05823363Phase 4Withdrawn
- Sponsor
- Jefferson Drapkin
- Start
- Sep 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Jefferson Drapkin. Primary endpoint: Pain reduction after surgery at 72 hours. Planned start Sep 2024; status: withdrawn.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05823363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823363.